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As of November 4th, 2020, thirty-six states and four territories (District of 
Columbia, Guam, Puerto Rico, and U.S. Virgin Islands) have approved a measure that 
regulates cannabis for medicinal use (Markle & Nativio, 2019). In particular, 
Pennsylvania law allows residents with twenty-three different medical conditions to 
apply for an ID card that will enable them to purchase medical marijuana from 
dispensaries. Some of the medical conditions included are anxiety disorders, autism, 
epilepsy, and post-traumatic stress disorder (PTSD). As more states approve marijuana 
for medicinal use, researchers continue to investigate the interaction between medicinal 
cannabis and the endocannabinoid system.  
 The cannabis plant consists of about 100 molecules called phytocannabinoids, 
with the two most studied as delta-9-tetrahydrocannabinol (THC) and cannabidiol 
(CBD). THC is responsible for the intoxicating effects of cannabis due to its action on 
CB1 cannabinoid receptors (Arnold, 2020). Clinical trial results have shown that THC is 
efficacious in chronic pain and spasticity in multiple sclerosis, among other symptoms. 
Other research studies have shown CBD to be effective in treating epilepsy and anxiety. 
However, CBD has a wide range of pharmacological actions without any euphoric 
effects. Although CBD and THC produce different results, both molecules enter the brain 
through the endocannabinoid system. This system is essential for modulating many organ 
systems, including the central and peripheral nervous systems. Within this system, there 
are two receptors that THC and CBD can bind to, cannabinoid 1 and 2 (CB1 and CB2) 




trials where altered doses of cannabis showed a reduction in pain intensity for patients 
with neuropathic pain. 
 Previous clinical findings, case studies, and focus group research have shown that 
consistent use of CBD in the endocannabinoid system effectively reduces seizures in 
epileptic patients and reduces nightmares and irritability of PTSD patients (Krediet et al., 
2020). As research continues to look into the endocannabinoid systems’, painstaking 
efforts are underway to analyze the proper THC and CBD ratio in medicinal cannabis 
patients. This paper investigates the effects of medicinal cannabis on patients with 








 In Pennsylvania, residents can apply for a special ID card that permits them to 
purchase medical marijuana for twenty-three different medical conditions, including 
anxiety disorders, autism, and neurodegenerative diseases. As more states legalize 
medicinal cannabis, researchers continue to investigate the relationship between this 
scheduled one controlled substance and the endocannabinoid system. This paper 
examines medicinal cannabis’s effects on patients with anxiety, PTSD, and epilepsy. The 
goal is that through a detailed understanding of medicinal cannabis’s effects, patients will 
have an alternative treatment for their symptoms. 
Anxiety Disorder 
 Anxiety disorders are the most prevalent mental disorder, with about thirty 
percent of individuals affected throughout the world (Turna et al., 2019). This general 
term includes generalized anxiety disorder, panic disorder, agoraphobia, social anxiety 
disorder, and specific phobias. Overall, anxiety is an incapacitating signal that warns an 
individual of imminent danger (Premoli et al., 2019). A distinguishing feature of anxiety 
disorders is an individual’s inability to establish signs to differentiate between safety and 
hazard feelings. This disorder has multiple comorbidities, including personality disorders, 
substance use disorders, depression, and medical conditions such as asthma and 




When someone is frightened or nervous, a stimulus activates certain brain areas, 
which can be detected with a PET scan (Martin et al., 2009). For example, in individuals 
with panic disorder, scientists have found an overall decrease in cerebral blood flow and 
an elevated metabolism of glucose in the amygdala and hippocampus (Martin et al., 
2009). Conversely, patients with a social anxiety disorder/social phobia had a 
hyperactivation of the amygdala supplemented with increased activity in the left 
postcentral gyrus and the middle temporal and right inferior frontal gyrus (Martin et al., 
2009). Martin et al. 2009 realized and observed in generalized anxiety disorder an 
elevated ratio of grey matter to white matter in superior portions of the temporal lobe, 
resulting in high activation of the insular cortex and amygdala (Martin et al., 2009).  
There are various treatments for anxiety disorder, but first-line treatments include 
psychotherapy such as Cognitive Behavioral Therapy (CBT) and pharmacotherapy. CBT 
addresses negative cognitions to produce a positive behavior and affect. This type of 
psychotherapy is evidence-based that includes homework between counseling sessions, 
and has helped treat social and specific phobias, generalized anxiety, and panic disorders. 
Additionally, exposure therapy, which is a part of CBT, has benefited particular phobias. 
Specifically, clients will expose themselves to anxiety-provoking stimuli in a gradual list 
from least to most anxious. Through breathing and relaxation, the goal of CBT is for 
patients to hopefully become desensitized to the most painful and tense experiences 
(Corey, 2018). 
Nonetheless, medications such as selective serotonin reuptake inhibitors (SSRIs) 




with psychotherapy. Although about 50% of patients benefit from these treatments, Turna 
et al. 2017 commented that the remaining half continue to have lingering symptoms or 
non-compliant due to the inability to afford medication (Turna et al., 2017). Research into 
the cannabis plant has found that psychoactive ingredients such as cannabidiol (CBD) 
and delta-9-tetrahydrocannabinol (THC) produce anxiolytic effects. Thus, cannabis can 
be used as an alternative to traditional treatments. 
Post-Traumatic Stress Disorder 
 Post-Traumatic Stress Disorder (PTSD) is a stress-related and trauma disorder 
according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition 
(DSM-V). This disorder’s diagnosis includes exposure to a traumatic event, disturbing 
memories, adverse changes in mood and cognition, avoidance, hyperarousal, and 
increased reactivity to cues from a traumatic event (Shishko et al., 2018).  
 Brain imaging studies of PTSD patients show that hyperactivation of the 
amygdala with decreased prefrontal functioning and decreased activation of the 
hippocampus (Shishko et al., 2018). These differences lead to increased arousal, 
impulsivity, and flashbacks, among other symptoms associated with PTSD. Additionally, 
functional MRIs have shown that there is also a hyperactivation of the anterior cingulate 
cortex, which is responsible for emotional and impulsive behavior (Martin et al., 2009). 
Also, there are neurotransmitter imbalances due to the lack of a response to external 
stressors that result in a decreased serotonin and an increase in norepinephrine and 




 Treatments for PTSD are similar to anxiety disorder. First-line therapies are 
SSRIs, which modulate neurotransmitter imbalance and the hyperactivation of the 
amygdala. Additionally, a specific type of exposure therapy called eye movement 
desensitization and reprocessing (EMDR) combines with SSRIs to reduce arousal. 
EMDR is a specific therapeutic technique that allows the patient to envision their 
traumatic experience while focusing on a therapist’s finger or hand (Corey, 2018). This 
approach also encompasses relaxation and breathing techniques. Despite the treatments 
used, about 20-30% of patients report a remission of symptoms (Shishko et al., 2018). 
This finding has led to an increased interest in cannabis and the endocannabinoid system.  
Epilepsy 
 Epilepsy is a prevalent neurological disorder characterized by transient 
disruptions in the brain (Leo et al., 2016). Typically, it is a condition that causes 
spontaneous yet frequent seizures due to glutamate hyperexcitability (Leo et al., 2016). 
Due to the number and severity of seizures, many patients will suffer from cognitive and 
behavioral abnormalities.  
 Epilepsy affects about 65 million people worldwide (Ong et al., 2020). This 
approximation includes 0.6% of children under 18, and 82% of those children will be 
under age 10. The most deleterious childhood epilepsies are called developmental and 
epileptic encephalopathies (DEEs) (Ali et al., 2019). One specific type of DEE is Dravet 
Syndrome. Mutations of the SCN1A gene responsible for creating sodium channels in the 
brain are the primary cause of this syndrome (Ali et al., 2019). This condition usually 




itself as a generalized tonic-clonic seizure, a type of seizure that affects both sides of the 
brain and correlates with a fever (Ali et al., 2019). Additionally, patients by the age of 
five may suffer from focal seizures and status epileptics, which can cause intellectual and 
developmental incapacities (Ali et al., 2019). However, this syndrome has a high 
mortality risk due to persistent seizures leading to the status epilepticus (Miller et al., 
2020). 
Although some antiepileptic drugs and surgeries can reduce seizures, many 
patients have treatment-resistant epilepsy (TRE). Park & Linder 2020 expressed TRE as a 
patient having  4 countable seizures per month (28 days) for at least two consecutive 
months and a history of trying at least four different antiepileptic therapies to get their 
epilepsy in control (Park et al., 2020). TRE affects nearly 30% of epileptic patients 
(Mitelpunkt et al., 2019). Typical antiepileptic treatments (AEDs) include valproate and 
carbamazepine, a ketogenic diet, and vagal nerve stimulation (Park & Linder Article). 
Leo et al. 2016 noted that the old and new AEDs were only present with side effects and 
negatively influenced a patient’s quality of life (Leo et al., 2016). Thus, scientists and 
researchers have taken great interest in the possible therapeutic effects of cannabis.  
 Cannabis may be helpful in the reduction of seizures due to its anticonvulsant 
activity. Leo et al. 2016 explained that cannabidiol might impact neuronal 
hyperexcitability by multiple mechanisms (Leo et al., 2016). These mechanisms include 
reducing the synaptic release of glutamate, activating serotonin receptors, and inhibiting 




seizure threshold by reducing seizure severity and frequency for more extended periods 
than typical AEDs (Dor & Ben-Zeev, 2020).   
Cannabis 
 Cannabis is a derivative of the Cannabis sativa plant and is the most commonly 
used drug worldwide (Turna et al., 2017). Although many consumers use cannabis for its 
euphoric and relaxing effects, this schedule one controlled substance has many 
therapeutic potentials. These effects are a result of the hundreds of phytocannabinoids 
that have been isolated in this plant, with the primary two being delta-9-
tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the primary 
phytocannabinoid responsible for varied sensory reactions and euphoria (Rong et al., 
2017). Researchers have also found that THC has anxiolytic and hypnotic effects that 
may help individuals with anxiety and anxiety-related disorders. 
 However, CBD is another psychoactive ingredient that differs in effects from 
THC. Anxiety disorders, chronic pain, and sleep disorders are among 4000 medical 
conditions that use cannabidiol (Bonaccorso et al., 2019). It differs in the psychoactive 
effects of THC, and many scientists have concluded that it can offset some 
neurobehavioral and cognitive effects of THC when both phytocannabinoids are 
administered together (Steenson & Chambers, 2019). Despite the differences between 
these phytocannabinoids, both of these ingredients act on the endocannabinoid system to 







 The endocannabinoid system consists of cannabinoid receptors, enzymes, and 
endogenous ligands. The two central receptors that THC and CBD bind to are 
cannabinoid type receptor-1 and receptor-2 (CB1 and CB2)  (Rong et al., 2017). The CB1 
receptor is primarily in the central nervous system. In contrast, the CB2 receptor is in 
immune cells throughout the body, mainly in the tonsils and spleen (Premoli et al., 2019). 
Since the 1960s, researchers have investigated the relationship between the 
endocannabinoid system and anxiety disorders. Viana et al. 2019 has discovered that if a 
compound (e.g., THC or CBD) inhibited the endogenous endocannabinoids, anandamide 
(AEA), and 2-arachidonoyl glycerol (2-AG), it would help to reduce anxious symptoms 
(Viana et al., 2019). 
 Nonetheless, researchers have found more information regarding the 
endocannabinoid system’s effects in individuals with Post-Traumatic Stress Disorder. 
Shishko et al. 2018 discovered that patients with this trauma and worry-related disorder 
have an increase in CB1 receptors that are not bound to a biological compound (Shishko 
et al., 2018). However, stimulation of CB1 receptors in the hippocampus, amygdala, and 
prefrontal cortex will relieve anxiety in these patients. For example, the amygdala has 
been the most promising since CB1 receptors can decrease stress, unpleasant memories, 
and fear. Furthermore, if a ligand or drug activates the CB1 receptors in the 
hippocampus, Shishko et al. 2018 explained that an individual would have a reduction in 
disturbing memories, hyperarousal, and hypervigilance (Shishko et al., 2018). The 




normalizing cortisol levels, reducing arousal in PTSD individuals. Hence, researchers 
indicate that CBT and exposure therapy reduce symptoms in anxiety and post-traumatic 
stress disorders. However, researchers hypothesize that THC and CBD can produce a 
more prolonged, sustained effect.  
Brain imagining studies have shown that the inhibition of AEA and 2-AG 
accompanies a reduction of aversive stimuli in the hippocampus and the ventromedial 
cortex. There is a hypothetical mechanism between the hypothalamus and the 
endocannabinoid system involved in alleviating panic symptoms. The primary target of 
investigation includes activation of CB1 and CB2 receptors at the hypothalamus, which 
prevents the hypothalamic-pituitary-adrenal axis (HPA) activation (Hillard et al., 2011). 
Viana et al. 2019 concluded from a study in mice that when CB1 and CB2 receptors 
activate 2-arachidonoyl glycerol, a subsequent decrease occurs in panic-like symptoms 
(Viana et al., 2019). Therefore, these findings substantiate the need to explore further the 







For this review, online library databases through Philadelphia College of 
Osteopathic Medicine were used, such as Academic Search Premier, Medline/PubMed, 
and ScienceDirect Journals. Keyword searches used were “medicinal cannabis,” 
“medicinal CBD,” “anxiety,” “PTSD,” and “epilepsy” for papers published between 2009 
to 2021. These articles were read for subject matter appropriateness and then evaluated 






REVIEW OF STUDIES ON CBD VS. CANNABIS ON 
ANXIETY, PTSD, AND EPILEPSY 
 
Cannabidiol in Anxiety and Sleep: A Large Case Series 
 Anxious symptoms are often associated with sleep concerns. Shannon, Lewis, 
Lee, & Hughes 2019 issued a retrospective study investigating whether CBD helped 
improve patients’ anxiety or sleep (Shannon et al., 2019). This study focused on the 
safety, tolerability, and acceptability of cannabidiol. One hundred and three adult patients 
began the study, but only 72 completed the research of which (n =25) had confirmed 
sleep or (n =47) anxiety disorder diagnosis. Many participants continued using other 
psychiatric medication, and the study lasted for three months. 
 Patients started on a 25 mg/d capsule of CBD, but many had an increase in dosage 
of 50 or 75 mg/d (Shannon et al., 2019). This increase occurred because of a rise in 
anxious symptoms or sleep complaints. Monthly, patients attended a clinic that measured 
their anxiety and sleep quality through two assessments, and a physical examination. 
 The first test was the Pittsburgh Sleep Quality Index. This exam computed sleep 
concerns and was a self-report that comprised a 19-item list with scores ranging from 0 to 
21. A higher score designated a decrease in sleep quality. An additional test, the 
Hamilton Anxiety Rating Scale measured anxious symptoms with fourteen questions. 
The assessment ranged in score from 0 to 56. A score of 17 or below suggested mild 




Additionally, patient self-evaluations indicated tolerability and side effects of 
cannabidiol. 
 Throughout the three-month study, not all patients completed the three follow-ups 
due to normal research attrition. At the first check-in, all 72 patients completed the 
treatment and assessments. By the second and third follow-up, 41 (56.9%) and 27 
(37.5%) patients continued the treatment process. 
 The summary of the results showed that sleep and anxiety symptoms decreased 
for the majority of patients. For example, at the first-month follow-up, 79.2% (57/72) 
improved their anxiety, and 6.7% (48/72) bettered their sleep quality (Shannon et al., 
2019). At the second follow-up, 78.1% (32/41) and 56.1% (23/41) enhanced their anxiety 
and sleep concerns. Thus, investigators stated that CBD treatment produced consistent 
results, especially in the anxiety group. For the sleep group, researchers observed mild 
improvement. Nevertheless, CBD was accepted, tolerated, and had minor adverse effects. 
The main side effect reported was fatigue.  
 Consequently, this study was open-label and lacked a placebo group for 
comparison. Other limitations included the sustained use of other medication and 
psychotherapy, limiting the efficacy of cannabidiol. Finally, the length of the study only 
monitored the acute effects of cannabidiol.  
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated 
public speaking test 
 Another diagnosable anxiety, social anxiety disorder/social phobia benefited from 




conducted a study that evaluated the acute effects of three diverse doses of cannabidiol 
versus placebo in participants in a simulated public speaking test (Linares et al., 2019). 
Fifty-seven male volunteers participated in the study and orally received cannabidiol 
(150,300, or 600 milligrams dissolved in corn oil) or placebo (corn oil) in a double-blind 
and randomized fashion.  
 Before the test, clinicians took the patient’s heart rates and blood pressures for 
baseline comparison. Participants also completed the Visual Analogue Mood Scale 
(VAMS). The VAMS is a sixteen-item list that assessed anxiety, sedation, cognitive 
impairment, and distress (Linares et al., 2019). Then, patients received a single oral 
placebo dose or cannabidiol one hour and thirty minutes before the test. For the speech, 
volunteers had two minutes to prepare a four-minute speech about “the public 
transportation system of your city” (Linares et al., 2019). The investigators also told them 
that the address would be recorded and later examined by psychiatrists and psychologists.  
 Before the speech, researchers measured anticipatory anxiety. Each volunteer 
stood in front of a television and began speaking. During each oration, investigators 
interrupted participants in the middle to assess VAMS and blood pressure. Directly after 
the speech and thirty minutes later, researchers completed the VAMS and blood pressure 
again. The public speaking test outcome exhibited that acute doses of CBD decreased 
anxiety (Linares et al., 2019). In particular, the VAMS indicated a U-shaped dose-
response curve. This curve meant that the lowest (150 mg) or highest (600 mg) doses of 




lowest anxiety level during the speech (Linares et al., 2019). However, the study only 
included men and was the major limitation. 
Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A 
human laboratory study 
 Obsessive-Compulsive Disorder (OCD) is an anxiety-related disorder described 
as repeated unpleasant thoughts and cyclic behaviors that causes substantial functional 
impairment (Gremel et al., 2016). Preclinical studies showed that the endocannabinoid 
system may adjust compulsive activities through CB1 projections that extend from the 
orbitofrontal cortex to the striatum (Kayser, Reilly R. et al., 2020). Gremel et al. (2016) 
reported that this connection functions in habitual and goal-directed behaviors.  
 Therefore, Kayser & Haney 2020 directed a placebo-controlled study that 
evaluated the effects of smoke cannabis in various CBD and THC concentrations in adult 
patients with OCD (Kayser et al., 2020). Researchers theorized that CBD and THC would 
reduce OCD symptoms. The study initially involved fourteen patients that were either 
male or female, but only twelve completed the final analysis. All participants received 
three different cannabis variations throughout three laboratory visits. These variants were 
approximately 800 mg of cannabis that were either the placebo, CBD (0.4% THC, 10.4% 
CBD), and THC (7.0% THC, 0.18% CBD) (Kayser et al., 2020). During each visit, 50% 
of a cigarette was smoked. Researchers monitored OCD symptoms during each session 
by using the Yale-Brown Obsessive-Compulsive Scale (YBOCS).  This assessment is a 
ten-item checklist that rates symptom severity. Patients also did self-assessments each 




State-Trait Anxiety Inventory (STAI-S), and the YBOCS-self assessment version (Kayser 
et al., 2020). The OCD-VAS measures severity of obsessions.   
 At the beginning of a visit, patients completed a toxicology report and learned 
how to smoke a THC cigarette. Specifically, investigators asked patients to inhale for five 
seconds, hold the smoke in for ten seconds, and exhale for forty seconds between puffs 
until smoking 50% of the cigarette (Kayser et al., 2020). After smoking, researchers 
measured heart rate, blood pressure, and self-evaluation of obsessions, compulsions, and 
anxiety at specific timepoints. These precise intervals were 20,40,60, 90, 120, and 180 
minutes after smoking (Kayser et al., 2020).  
 Trial outcomes indicated a decrease in scores for the YBOCCS and STAI-S. 
Interestingly, minute 40 displayed that STAI-S scores were significantly lower for the 
placebo and THC treatment phases only. However, at minute 60 and after, the STAI-S 
scores were relatively similar for all treatment groups (Kayser et al., 2020). 
Cardiovascular results revealed that THC had an increase in heart rate and blood 
pressure. Nevertheless, there were no severe side effects, but the most commonly 
reported were dry mouth and apprehension. 
 Overall, this study had four discoveries. First, THC, as in other preclinical and 
clinical studies, had an increase in cardiovascular effects. Self-assessments signified that 
OCD and anxious symptoms decreased over time for all three treatment groups. CBD and 
THC did not have a significant difference in symptoms in comparison to placebo. 
Participants in the placebo group had a more substantial reduction in anxiety in the first 




study had a small sample size, and the trial only assessed acute doses. The latter was 
because the study lasted approximately two months for each participant.  
Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-
Compulsive Disorder 
 First-line treatments for OCD are serotonin reuptake inhibitors (SSRIs) and 
cognitive behavioral therapy with a focus on exposure and response prevention (EX/RP) 
(Kayser et al., 2020). Thus, Kayser et al. 2020 performed a trial with nabilone, a THC 
synthetic form (Kayser, Reily et al., 2020). The clinical trial’s goal was to measure the 
acceptability, tolerance, and efficacy of nabilone, either alone or in combination with 
EX/RP in OCD adult patients. The trial lasted four weeks and included eleven patients, 
ages 18-60.  
 Patients were randomized and placed in two groups. The first only received 
nabilone, and the second received nabilone with EX/RP. The nabilone prescription was 1 
mg initially but decreased from 0.25 to 0.5 mg because of side effects (Kayser et al., 
2020). Tablets were consumed orally and taken twice a day. The EX/RP therapy sessions 
lasted for 90 minutes weekly and included eight exposure sessions. During exposure, 
patients encountered feared stimuli without making it a compulsion. At baseline, week 2, 
and week 4, investigators rated OCD and depression/anxiety symptoms through the 
YBOCS and Depression Anxiety Stress Scale, respectively (Kayser et al., 2020). For the 
second treatment group, therapists assessed the progress of EX/RP by utilizing the Patient 
EX/RP Rating Scale. Furthermore, participants met with a physician weekly to measure 




investigators asked the study sample to return to complete a final follow-up that 
addressed the previous measures. 
 Data analysis indicated a more significant decrease in symptoms for the nabilone 
treatment group with EX/RP. Additionally, there was no significant difference in the 
Depression Anxiety Stress Scale between the two groups. Altogether, investigators 
concluded that the study participants accepted and well-tolerated nabilone. The reason for 
this is the absence of severe adverse effects. However, patients reported disorientation, 
difficulty concentrating, and a dry mouth (Kayser et al., 2020). 
 Moreover, the researchers gathered another sample with 21 patients who only 
participated in EX/RP. Investigators discovered that the amount of change in the nabilone 
plus EX/RP was twice as significant as EX/RP alone, which the YBOCS detected. The 
effects continued for another month after the study. 
 Conversely, this study had shortcomings. It had a minute sample size and lacked a 
control/placebo group for comparison. Finally, researchers noted that a larger clinical 
trial must occur to determine nabilone’s efficacy. 
Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series 
In 2018, Elms et al. published a retrospective chart review to see if PTSD adult 
patients treated with cannabidiol had symptom reduction (Elms et al., 2019). 
Additionally, the objective of the study analyzed the tolerance and efficacy of 
cannabidiol. The review lasted for eight weeks and included eleven patients. After the 
preliminary evaluation, researchers distributed the Post-Traumatic Stress Disorder 




that physicians and scientists use to determine a patient’s PTSD symptom severity. There 
are a total of 20 questions, with the highest score equating to eighty. Although any score 
on this exam confirms that a patient has PTSD, the study patients all received a baseline 
score of at least 33. This score indicates that they would likely benefit from treatment 
(Elms et al., 2019).  
Besides cannabidiol, many patients continued to receive psychiatric medication 
and psychotherapy. Medications encompassed mood stabilizers, anxiolytics, 
antidepressants, stimulants, and nearly 75% of patients engaged in cognitive behavioral 
therapy. Nonetheless, patients obtained cannabidiol in an oral liquid spray or oral 
capsule. The capsules contained 22-28 mg of cannabidiol, while the liquid spray 
contained 425 to 575 mg of CBD, with approximately 1.5 mg of CBD per spray (Elms et 
al., 2019). Researchers informed patients about taking cannabidiol once or twice per day, 
based on their symptom severity. Thus, the median dose daily for the capsule was 25 mg 
and 9 mg for the liquid spray (Elms et al., 2019).    
 Results exhibited a baseline average score of 51.82 on the PLC-5. Nevertheless, 
after four weeks of treatment, ninety-one percent of patients reported a 21% decrease, 
51.82 to 40.73 (Elms et al., 2019). At eight weeks, nearly 75% (73%) had an even more 
significant reduction in their symptoms which was 9%, and the PLC-5 indicated a new 
score of 37.14. During the four to eight-week period, half of the patients described an 
improvement in their nightmare since starting their cannabidiol dosage (Elms et al., 




This improvement meant that CBD resulted in patients having a better mood, increased 
focus, and decreased anxiety (Elms et al., 2019).  
 These studies indicated that patients had an overall reduction in their PTSD 
symptoms in two months, as evaluated by the PLC-5. Moreover, investigators did not 
find a difference between those taking the oral capsule or liquid spray. This study pointed 
out that not only does cannabidiol help reduce PTSD symptoms such as intrusive 
memories of traumatic experiences and an increased level of arousal, but it also reduced 
nightmares. CBD did not exacerbate or minimize side effects seen with other 
medications. The study’s shortcomings included a lack of an exact CBD dose for all 
patients and a small sample size that was predominantly female (Elms et al., 2019).  
Experiences with medical cannabis in the treatment of veterans with PTSD: Results 
from a focus group discussion 
There are several anecdotal reports and focus groups that describe the relationship 
between PTSD and medicinal cannabis. Focus groups are beneficial for researchers 
because they allow them to draw conclusions about cannabis as a therapeutic and apply 
them to a larger population. For example, in 2018, the Netherlands Military Mental 
Health Service produced a qualitative focus group study that observed the opinion and 
experience of PTSD symptomatology (Krediet et al., 2020).  
Ten veterans diagnosed with chronic PTSD and recurrent insomnia and 
nightmares participated in a focus group. They were treated by a psychiatrist on-site, and 
the study lasted for two hours. The psychiatrist, psychologist-researcher, and pharmacist-




the use, administration, and effect of medical cannabis. Also, they discussed the 
comparison of medical cannabis with other psychiatric medications, the stigma of 
medicinal cannabis, and its availability. The results revealed that the study sample was 
all-male, and they were between the ages of 42 and 66 (Krediet et al., 2020). All of the 
patients had various prescriptions of cannabis strains with different ratios of 
tetrahydrocannabinol and cannabidiol. There was no exact administration route, but many 
administered it sublingually (Krediet et al., 2020).  
 In the beginning, patients first discussed their experience with previous 
treatments. Most were in agreement that other medications resulted in symptoms severity 
remaining the same and several adverse effects. Examples of side effects were stomach 
pain, drunkenness, and liver problems. Some were hesitant to start a prescription in terms 
of stigma because of drug abuse worries and getting “high.” Many of the times, this 
perception originated from childhood where patients encountered family members using 
it recreationally. Thus, patients never considered cannabis having medicinal effects.  
 In terms of therapeutic effects, participants conveyed an increase in sleep quality 
and relaxation while experiencing a reduction in nightmares and anger (Krediet et al., 
2020). Additionally, participants had less pain with headaches, and many did not suffer 
from any adverse effects. Therefore, some patients discontinued their mood stabilizers 
and antidepressants.  
 Conversely, the research had a small sample and lacked an exact dosage. 
However, this focus group indicated a span of therapeutic effects. Researchers also 




THC. Lastly, depending on symptom severity duration, patients either took their 
prescription before going to sleep or during the day. 
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs. Placebo on Convulsive 
Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial 
 In 2016, Miller & Ingrid performed a clinical trial to discuss the efficacy and 
safety of cannabidiol in children with Dravet syndrome (Miller et al., 2020). This trial 
was a “multicenter double-blind, randomized, placebo-controlled, parallel-group” that 
involved 198 patients from 43 clinical centers (Miller et al., 2020). This 34-week study 
consisted of a four-week baseline period, followed by a 14-week treatment period, 
resulting in 12 weeks of stable dosing and a four-week follow-up period.  
 For patients to be involved in the study, they had to be between the ages of two 
and eighteen and have at least four uncontrollable seizures during the four-week baseline 
period. Caregivers recorded these seizures at their first visit with the Independent 
Epilepsy Study Consortium. Once patients met the criteria, they returned for a second 
visit where they either received a placebo or highly purified cannabidiol, which were both 
supplied in 100 mL amber glass bottles (Miller et al., 2020). The trial’s medication was 
given out twice daily for the placebo group, and the two treatment groups reached either 
10 (CBD10) or 20 (CBD20) mg/kg per day. The trial started with two divided doses 
starting at 2.5 mg/kg/d. It then increased to 10 mg/kg/d on day seven and finally a 20 
mg/kg/d dose on the eleventh day.  
The trial had two significant outcomes. The first was to observe the change in 




point. Additionally, researchers were looking for changes in all seizure frequency during 
the treatment period, the proportion of patients with at least 50% reduction from baseline, 
and an overall score change in the Caregiver Global Impression of Change (CGIC) 
(Miller et al., 2020). The CGIC measures a difference in patient severity, which the 
caregiver rates on a scale from 1-7, with 1 indicating extreme improvement. 
The trial results showed that within the primary outcome, the percentage 
reduction from baseline in convulsive seizures for the 10 mg/kg/d was 48.7. The 
20mg/kg/d group and the placebo group had 45.7% and 26.9% reductions, respectively 
(Miller et al., 2020). Also, secondary outcome results illustrated that there was 56.4%, 
47.3%, and 26.2% decreases in total seizures of the CBD10, CBD20, and placebo group 
(Miller et al., 2020). The percentage of patients achieving at least a 50% reduction from 
baseline in seizure frequency was 26.2% for the placebo group. The treatment groups had 
a more significant increase, 43.9%, and 49.3%, for CBD10 and CBD20 groups (Miller et 
al., 2020). 
Despite the therapeutic effects of cannabidiol in the patients, nearly 89% of them 
suffered from adverse effects (AEs). The five most popular AEs were fatigue, diarrhea, 
decreased appetite, somnolence, and a high fever (Miller et al., 2020). 
Thus, this randomized clinical trial showed that both prescriptions of cannabidiol 
considerably decreased convulsive seizures compared to the placebo group. However, 
there were a few limitations to the study. These drawbacks included patients under the 
age of 18, a report that lacked long-term results, and a shortage of diversity within 




Long-term safety and efficacy of highly purified cannabidiol for treatment-
refractory epilepsy 
In 2019, Gaston et al. performed an open-label study that assessed the quality of 
life in children and adults in Alabama with TRE for one year (Gaston et al., 2021). After 
researchers determined that eighty patients fell under the inclusion criteria, they started 
their cannabidiol dosage. The initial prescription was 5 mg/kg/day, with the dose 
increasing every two weeks by the addition of 5 mg/kg/day (Gaston et al., 2021).   
Furthermore, researchers also incorporated three different questionnaires called 
the QOLIE-89, POMS, and the AEP recorded at the beginning and end of the treatment 
phase. The QOLIE-89 is an assessment that tests the quality of life in epilepsy. If there 
was a 10-point change, scientists considered it to be clinically significant. POMS tested 
six moods: anxiety, depression, anger, vigor, fatigue, and confusion (Gaston et al., 2021). 
Finally, the AEP was a survey that examined adverse events.  
However, the most important outcome that researchers studied was seizure 
frequency and severity. Before the treatment period, caregivers or patients completed a 
seizure calendar for three months. Once the study started, patients were required to visit 
researchers nearly every two weeks. During the biweekly visits, clinicians used the 
Chalfont Seizure Severity Scale (CSSS) to measure seizure severity. Precisely, the CSSS 
measures the unsettling aspects of seizures: the length of the seizure, the amount of time 
it takes to return to baseline, and any related injuries (Gaston et al., 2021). A higher score 
correlated with an increase in seizure severity and a ten-point improvement designated 




 After a year, researchers discovered clinically significant improvements in total 
seizure count, QOLIE-89, POMS, and AEP scores. For example, the QOLIE-89 score at 
the start of the study was 49.4, and it increased to 57 (Gaston et al., 2021). Although the 
improvement was not exactly ten points, researchers observed clinically and statistically 
significant improvements. Conversely, there was a negative correlation between the 
POMS score and mood.  
Moreover, at the start of research analysis, 28.3% of patients had more than fifty 
seizures every two weeks, but at one year, only 13.2% remained at that amount (Gaston 
et al., 2021). Approximately 30% of the sample had 14-50 seizures every two weeks 
before treatment, and now only 24.5% have that same amount a year later. Finally, 41.5% 
of patients had < 14 seizures/2 weeks at the beginning of the study, and now over half, 
62.3%, have this quantity at follow-up (Gaston et al., 2021). These changes were 
significant as the CSSS score decreased from 80.9 to 28.9, which signified clinical 
efficacy.  
Altogether, researchers concluded that cannabidiol treatment demonstrated 
clinically significant results in seizure severity, frequency, and duration. Nonetheless, the 
medication increased mood, which directly led patients to document that their quality of 
life increased overall (Gaston et al., 2021). Despite the success of the treatment plan, the 
study was an open-label trial. Thus, the lack of a placebo or control group did not allow 
researchers to fully understand the effectiveness of cannabidiol in terms of seizure 




Cognitive function and adaptation skills after a one-year trial of cannabidiol (CBD) 
in a pediatric sample with treatment-resistant epilepsy 
Additionally, behavioral effects in TRE patients require testing. In 2019, 
Thompson et al. analyzed a study that observed functional or cognitive effects in TRE 
pediatric patients using cannabidiol as a remedy for one year (Thompson et al., 2020). 
Participants in the study ranged in age from 3 to 19 years old and began taking 5 
mg/kg/day of Epidiolex (CBD) split into two doses taken during the morning and 
evening. Hence, the study sample took their Epidiolex at the same time as their 
antiepileptic treatments.  
The NIH Toolbox Cognition Battery (NIHTB-CB) assessed the cognitive 
functioning of patients. Notably, this exam measures participants’ sensory, motor, 
mental, and emotional function by looking at brain functions such as attention, memory, 
executive functioning, and language (Thompson et al., 2020). Researchers implemented 
the Adaptive Behavior Assessment System- Second Edition (ABAS-II) that examined 
functional status by looking at three domains: practical, social, and conceptual. Practical 
evaluated self-care and home living skills. Social assessed engagement in leisure and 
social behaviors and conceptual was the caregiver’s rating of the patient’s ability to 
function in communication and academic environments (Thompson et al., 2020).  
Though the open-label study commenced with 87 children, only 38 completed 
assessments at the beginning and follow-up. Researchers determined an insignificant 
change in cognition and functional adaptive skills, but there was an overall improvement 




effectiveness in decreasing seizure frequency. Additionally, researchers concluded that 
cannabidiol did not cause any adverse effects that affected cognitive function. However, 
drawbacks for this research included a smaller number of patients. Besides, some 
participants could not take the NIHTB-CB because they had nonverbal impairments 








RECOMMENDATIONS FOR FUTURE STUDIES 
 
Researchers are currently implementing clinical tests with larger samples to 
address medicinal cannabis’s effects on anxiety disorders, PTSD, and epilepsy. For 
instance, in April 2021, at McMaster University in Hamilton, Ontario, Canada, 
investigators estimated that they would begin an eight-week randomized, placebo-
controlled trial to evaluate the effects of CBD in generalized and social anxiety disorder, 
panic disorder, and agoraphobia (Van Ameringen et al., 2020). 
 Specifically, clinical trials need to have an extended treatment period. The 
majority of studies in this review lasted for less than a year, which limited the efficacy of 
cannabidiol. However, this could be partly due to adverse effects and lack of a safety 
profile for cannabis. In addition to this, many of the studies did not include a placebo 
group. It is hard to determine if cannabis is well-tolerated and accepted for a larger 
patient population without a group for comparison.  
In the future, studies should observe if different routes of administration lead to 
various effects. Many patients in this literature review consumed treatments sublingually, 
but smoking or dermal creams may produce a faster or more long-term impact. 
Additionally, researchers should continue investigating different forms of cannabis and 
their effects. In the PTSD study with oral cannabidiol, investigators did not observe a 
difference in the liquid spray and capsule response. Still, an oral tablet or drinkable liquid 




Moreover, researchers need to continue investigating an effective dose that can 
apply to a multitude of patients. In the Dravet Syndrome study, researchers found that 
both prescriptions, 10 and 20 mg/day were efficacious. Yet, lower dosages may be more 
effective when used with routine medication, leading to reduced symptoms and improved 
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